The LPA1/LPA3 dual antagonist SAR100842 has completed phase II clinical trials for systemic sclerosis [73], and the LPA1/LPA3 inhibitors Ki16425, Ki16198, and Debio 0719 have been tested in mouse cancer models [74–76]. Here, LPAR1 is linked to systemic sclerosis.